Breakthroughs Ddss
Celena Holtzberg
Bioorthogonal chemistry reactions occur in physiological conditions without interfering with normal physiological processes. Through metabolic engineering, bioorthogonal groups can be tagged onto cell membranes, which selectively attach to cargos with paired groups via bioorthogonal reactions. Due to its simplicity, high efficiency, and specificity, bioorthogonal chemistry has demonstrated great application potential in drug delivery. On the one hand, bioorthogonal reactions improve therapeutic agent delivery to target sites, overcoming off-target distribution. On the other hand, nanoparticles and biomolecules can be linked to cell membranes by bioorthogonal reactions, providing approaches to developing multi-functional drug delivery systems (DDSs). In this review, we first describe the principle of labeling cells or pathogenic microorganisms with bioorthogonal groups. We then highlight recent breakthroughs in developing active targeting DDSs to tumors, immune systems, or bacteria by bioorthogonal chemistry, as well as applications of bioorthogonal chemistry in developing functional bio-inspired DDSs (biomimetic DDSs, cell-based DDSs, bacteria-based and phage-based DDSs) and hydrogels. Finally, we discuss the difficulties and prospective direction of bioorthogonal chemistry in drug delivery. We expect this review will help us understand the latest advances in the development of active targeting and multi-functional DDSs using bioorthogonal chemistry and inspire innovative applications of bioorthogonal chemistry in developing smart DDSs for disease treatment.
Extracellular vesicles (EVs) are a class of cell-derived lipid-bilayer membrane vesicles secreted by almost all mammalian cells and involved in intercellular communication by shuttling various biological cargoes. Over the last decade, EVs - namely exosomes and microvesicles - have been extensively explored as next-generation nanoscale drug delivery systems (DDSs). This is in large due to their endogenous origin, which enables EVs to circumvent some of the limitations associated with existing cancer therapy approaches (i.e. by preventing recognition by the immune system and improving selectivity towards tumor tissue). However, successful translation of these cell-derived vesicles into clinical applications has been hindered by several factors, among which the loading of exogenous therapeutic molecules still represents a great challenge. In order to address this issue and to further advance these biologically-derived systems as drug carriers, EV-biohybrid nano-DDSs, obtained through the fusion of EVs with conventional synthetic nano-DDSs, have recently been proposed as a valuable alternative as DDSs. Building on the idea of "combining the best of both worlds", a combination of these two unique entities aims to harness the beneficial properties associated with both EVs and conventional nano-DDSs, while overcoming the flaws of the individual components. These biohybrid systems also provide a unique opportunity for exploitation of new synergisms, often leading to improved therapeutic outcomes, thus paving the way for advancements in cancer therapy. This review aims to describe the recent developments of EV-biohybrid nano-DDSs in cancer therapy, to highlight the most promising results and breakthroughs, as well as to provide a glimpse on the possible intrinsic targeting mechanisms of EVs that can be bequeathed to their hybrid systems. Finally, we also provide some insights in the future perspectives of EV-hybrid DDSs.
Given that other reviews have detailed the contribution of bioorthogonal chemistry for cancer imaging, prodrug activation, and cancer therapy but do not detail the application of bioorthogonal chemistry from the developing strategies of DDSs,77,78 this review will focus on recent advances in bioorthogonal chemistry (especially SPAAC and iEDDA) in developing DDSs from the perspective of active targeting and multi-functional modifications. We introduced the principle of labeling cells or pathogenic microorganisms with bioorthogonal reactions, including bioorthogonal groups, labeling biomolecules, and labeling strategies in vitro and in vivo. We then highlighted recent breakthroughs in developing active targeting DDSs to tumors, immune systems or bacteria via bioorthogonal chemistry, and its applications in developing functional bio-inspired DDSs. Finally, we discussed the challenges and prospective direction of bioorthogonal chemistry from precision regulation, expansion of toolkit and technology integration for designing novel DDSs. We expect this review will help researchers to overview latest advances in designing active targeting and multi-functional DDSs with bioorthogonal chemistry, and inspire innovative new drugs for disease treatment.
In addition to traditional appliances and clear ceramic braces, we use the latest innovative technology, such as Invisalign, to enhance your smile through increased comfort and more efficient treatment. We keep our office on the forefront of technological breakthroughs to provide the best orthodontic care possible.
We keep our office on the forefront of technological breakthroughs by utilizing digital imaging. Our office is one of the few in Central Ohio to feature 3D imaging for our patients. We also offer the latest in orthodontic braces, such as clear braces, 3M Unitek bracket systems and Invisalign clear aligners, to make your treatment faster and/or more comfortable. Additionally, our office is completely paperless. This use of digital technology gives our patients access to their appointments and account information through this website. These technological advancements ensure we can provide the best orthodontic care possible.
Dr. Kevin Hou earned his doctorate degree from the University of Washington where he was trained in patient-centered care. His primary focus as a care provider is to communicate to patients clearly so that they feel informed and empowered to make confident decisions about their treatment plan. As someone passionate about newest breakthroughs in dental technology he immerses himself in continuing education opportunities.
Dr. Pham understands the necessity of staying abreast of scientific breakthroughs. Every year, new discoveries are made that enhance the dental health of many discoveries that point the way to minimally invasive dental procedures, quicker recovery, and new cosmetic oral procedures. Dr. Pham watches these advances, and when he is sure they are viable and beneficial to his patients, he adds them to his oral health expertise and practices so that they can be offered to his patients. To point, Dr. Pham's office boasts some of the most advanced and comprehensive sterilization and pathos-clinical barrier practices available in the dental community, in addition to the latest oral cosmetic treatments and treatment of caries.
Dr. Ronald H. Jarvis, who helped make breakthroughs in reconstructive dentistry and applied those new discoveries in his clinical work, died May 26 in Millard Fillmore Suburban Hospital, Amherst, after a brief illness. He was 85.
We're fortunate to live on the right side of healthcare history. We enjoy the benefits of wide-ranging advancements and the promise of new breakthroughs every day. As a result, dentistry continues to offer innovative solutions for comfortable, safe treatment.
One of the most important breakthroughs in recent dentistry is dental implants. When teeth are lost to any number of causes, dental implants can provide an effective, permanent solution. The dental implants provide a strong foundation for a fixed or removable restoration to replace the lost tooth structure.
In November 2022, she received the award for her research and findings, making her the first dentist to win a Mitacs Award. Joining Dr. Maucoski as the other 2022 Mitacs Award winners (after receiving roughly 400 award applications) includes a researcher who found breakthroughs in regards to prostate cancer, one who created AI that detects heart disease, a scholar who invented revolutionary tech for toxic clean-ups, and another who developed an app to improve the lives of people with disabilities.
aa06259810